With metastatic triple negative E7080 randomized chemotherapy were obtained with or without iniparib. The study is not true prim with pre-specified criteria for the importance of their cooperation to meet Ren endpoints of OS and PFS. It was, however, an improvement in overall survival and progression-free survival in patients in the second and third line treatment. The analysis of S H Rte showed that the addition of iniparib not to toxicity Tsprofil add of gemcitabine and carboplatin. Using iniparib in TNBC is currently being tested in the neoadjuvant, and in the treatment of brain metastases. Veliparib, an oral PARP and PARP is also under consideration. He also showed in combination with metronomic cyclophosphamide tolerated and an activity t In TNBC.
Veliparib with GSK-3 Inhibitors temozolomide, an agent as synergistic in xenograft models of breast cancer has been shown to the activity of t Have in patients with metastatic breast cancer. Although vorl INDICATIVE data from this phase II study does not include an analysis of sub-TNBC were completely Ndigen results and the effectiveness of last year are still Exh Constantly. All TNBC patients benefit from PARP inhibitors or if only part of TNBC patients, such as BRCA-deficient tumors clinical improvement over chemotherapy alone have remains to be seen. The clinical utility of PARP inhibitors k can be better achieved When pr Predictive biomarkers can be identified k. Of anti-angiogenic VEGF anti Numerous studies have demonstrated the bevacizumab for the treatment of metastases examined and analyzes show that subsets of TNBC can call a erh Hte sensitivity to anti-angiogenic agents.
Several studies look at the addition of bevacizumab to various chemotherapy drugs have Including an increase in progression-free survival time in patients with TNBC Several randomized multicenter studies Shown Lich of the Cancer and Leukemia Group B and the National Surgical Adjuvant Breast and c lon Study Project B, hoping to gather more data on the effect of bevacizumab in TNBC. But as Greenberg and Rugo erw Reconciled, all tests have so far been PFS as an endpoint and an improvement in overall survival has not been demonstrated using. In the end, the FDA began the process to remove breast cancer as an indication of the label Avastin not only because of lack of efficacy, but safety.
A meta-analysis in JAMA underlined the dangers of drugs, saying that chemotherapy alone, the addition of bevacizumab in conjunction with increased FITTINGS risk for t Dliche side effects were compared, bleeding are the hours most common, Neutropenia, and perforation of the gastrointestinal tract . Although there were differences in the relative risk between the different tumor types and between drug doses and combinations, he warned of the m Resembled erh FITTINGS risk of FAE, especially when pairing drug bevacizumab with taxanes or platinum. EGFR inhibitors cetuximab monotherapy seems low activity t in metastatic triple-negative and so recent research has had on the search for the right partner for therapeutic monoclonal Concentrated body. Cetuximab in combination with platinum salts had encouraging results. Carey et al’s study showed little reaction to cetuximab group, but patients U again cetuximab with carboplatin had a response rate and I saw a clinical benefit.